Characteristics of Gastrointestinal Bleeding After Placement of Continuous-Flow Left Ventricular Assist Device: A Case Series

Digestive Diseases and Sciences

Volumn 60, Issue 6, 2015, Pages 1859-1867

  Marsano, Joseph ^a   Desai, Jay ^a   Chang, Shannon ^a   Chau, Michelle ^b   Pochapin, Mark ^a   Gurvits, Grigoriy E ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b POPULATION COUNCIL   (United States)

Author keywords

Gastrointestinal bleeding; LVAD; Push enteroscopy; Small bowel

Indexed keywords

ACETYLSALICYLIC ACID; HEMOGLOBIN; WARFARIN;

ADULT; ANGIODYSPLASIA; ARTICLE; BRAIN HEMORRHAGE; CLINICAL ARTICLE; CONTINUOUS FLOW LEFT VENTRICULAR ASSIST DEVICE; DOUBLE BALLOON ENTEROSCOPY; ELECTRONIC MEDICAL RECORD; ESOPHAGOGASTRODUODENOSCOPY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART TAMPONADE; HEMATURIA; HEMOSTASIS; HUMAN; MALE; PRIORITY JOURNAL; PUSH ENTEROSCOPY; RETROSPECTIVE STUDY; TERTIARY CARE CENTER; ADVERSE EFFECTS; AGED; HEART ASSIST DEVICE; MIDDLE AGED; RISK FACTOR;

ADULT; AGED; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART-ASSIST DEVICES; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84930383435     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-015-3538-7     Document Type: Article

References (35)

1. Birks EJ. A changing trend toward destination therapy: are we treating the same patients differently? Tex Heart Inst J. 2011;38:552–554.
2. Slaughter MS, Pagani FD, Rogers JG, et al. Clinical management of continuous-flow left ventricular assist devices in advanced heart failure. J Heart Lung Transplant. 2010;29:S1–S39.
3. Szycher M, Clay W, Gernes D, et al. Thermedics’ approach to ventricular support systems. J Biomater Appl. 1986;1:39–105.
4. Griffith BP, Kormos RL, Borovetz HS et al. HeartMate II left ventricular assist system: from concept to first clinical use. Ann Thorac Surg. 2001;71:S116–S120; discussion S114–S116.
5. Goldstein DJ. Worldwide experience with the MicroMed DeBakey Ventricular Assist Device as a bridge to transplantation. Circulation. 2003;108:II272–II277.
6. Frazier OH, Myers TJ, Westaby S, et al. Clinical experience with an implantable, intracardiac, continuous flow circulatory support device: physiologic implications and their relationship to patient selection. Ann Thorac Surg. 2004;77:133–142.
7. Esmore DS, Kaye D, Salamonsen R, et al. First clinical implant of the VentrAssist left ventricular assist system as destination therapy for end-stage heart failure. J Heart Lung Transplant. 2005;24:1150–1154.
8. Miller LW, Pagani FD, Russell SD, et al. Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med. 2007;357:885–896.
9. John R, Lee S. The biological basis of thrombosis and bleeding in patients with ventricular assist devices. J Cardiovasc Transl Res. 2009;2:63–70.
10. Starling RC, Moazami N, Silvestry SC, et al. Unexpected abrupt increase in left ventricular assist device thrombosis. N Engl J Med. 2014;370:33–40.
11. John R, Kamdar F, Liao K et al. Improved survival and decreasing incidence of adverse events with the HeartMate II left ventricular assist device as bridge-to-transplant therapy. Ann Thorac Surg. 2008;86:1227–1234; discussion 1234–1225.
12. Gullov AL, Koefoed BG, Petersen P. Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation: the AFASAK 2 study. Atrial Fibrillation Aspirin and Anticoagulation. Arch Intern Med. 1999;159:1322–1328.
13. Stern DR, Kazam J, Edwards P, et al. Increased incidence of gastrointestinal bleeding following implantation of the HeartMate II LVAD. J Card Surg. 2010;25:352–356.
14. Uriel N, Pak SW, Jorde SP, et al. Acquired von Willebrand syndrome after continuous-flow mechanical device support contributes to a high prevalence of bleeding during long-term support and at the time of transplantation. J Am Coll Cardiol. 2010;56:1207–1213.
15. Crow S, John R, Boyle A, et al. Gastrointestinal bleeding rates in recipients of nonpulsatile and pulsatile left ventricular assist devices. J Thorac Cardiovasc Surg. 2009;137:208–215.
16. Demirozu ZT, Radovancevic R, Hochman LF, et al. Arteriovenous malformation and gastrointestinal bleeding in patients with the HeartMate II left ventricular assist device. J Heart Lung Transplant. 2011;30:849–853.
17. Heyde E. Gastrointestinal bleeding in aortic stenosis. N Engl J Med. 1958;259:196–200.
18. Massyn MW, Khan SA. Heyde syndrome: a common diagnosis in older patients with severe aortic stenosis. Age Ageing. 2009;38:267–270.
19. Warkentin TE, Moore JC, Anand SS, et al. Gastrointestinal bleeding, angiodysplasia, cardiovascular disease, and acquired von Willebrand syndrome. Transfus Med Rev. 2003;17:272–286.
20. Suarez J, Patel CB, Felker GM, et al. Mechanisms of bleeding and approach to patients with axial-flow left ventricular assist devices. Circ Heart Fail. 2011;4:779–784.
21. Slaughter MS, Sobieski MA, Gallagher C, et al. Fibrinolytic activation during long-term support with the HeartMate II left ventricular assist device. ASAIO J. 2008;54:115–119.
22. Klovaite J, Gustafsson F, Mortensen SA, et al. Severely impaired von Willebrand factor-dependent platelet aggregation in patients with a continuous-flow left ventricular assist device (HeartMate II). J Am Coll Cardiol. 2009;53:2162–2167.
23. Meyer AL, Malehsa D, Bara C, et al. Acquired von Willebrand syndrome in patients with an axial flow left ventricular assist device. Circ Heart Fail. 2010;3:675–681.
24. Morishima A, Marui A, Shimamoto T, et al. Successful aortic valve replacement for Heyde syndrome with confirmed hematologic recovery. Ann Thorac Surg. 2007;83:287–288.
25. Goda M, Jacobs S, Rega F, et al. Time course of acquired von Willebrand disease associated with two types of continuous-flow left ventricular assist devices: HeartMate II and CircuLite Synergy Pocket Micro-pump. J Heart Lung Transplant. 2013;32:539–545.
26. Olmos JA, Marcolongo M, Pogorelsky V, et al. Argon plasma coagulation for prevention of recurrent bleeding from GI angiodysplasias. Gastrointest Endosc. 2004;60:881–886.
27. Kwan V, Bourke MJ, Williams SJ, et al. Argon plasma coagulation in the management of symptomatic gastrointestinal vascular lesions: experience in 100 consecutive patients with long-term follow-up. Am J Gastroenterol. 2006;101:58–63.
28. Boley SJ, Brandt LJ. Vascular ectasias of the colon—1986. Dig Dis Sci. 1986;31:26S–42S.
29. Masso Gonzalez EL, Garcia Rodriguez LA. Proton pump inhibitors reduce the long-term risk of recurrent upper gastrointestinal bleeding: an observational study. Aliment Pharmacol Ther. 2008;28:629–637.
30. Rennyson SL, Shah KB, Tang DG, et al. Octreotide for left ventricular assist device-related gastrointestinal hemorrhage: can we stop the bleeding? ASAIO J. 2013;59:450–451.
31. Bowers M, McNulty O, Mayne E. Octreotide in the treatment of gastrointestinal bleeding caused by angiodysplasia in two patients with von Willebrand’s disease. Br J Haematol. 2008;108:524–527.
32. Rossini FP, Arrigoni A, Pennazio M. Octreotide in the treatment of bleeding due to angiodysplasia of the small intestine. Am J Gastroenterol. 1993;88:1424–1427.
33. Boesby L, Christensen NJ, Kristensen LO. Somatostatin analogues in the treatment of bleeding GI-angiodysplasias. Ugeskr Laeger. 2008;170:958.
34. Mannucci PM. Treatment of von Willebrand disease. Thromb Haemost. 2001;86:149–153.
35. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138:1093–1100.